RNA Methylation Protein HNRNPC Drives T-Cell Leukemia Growth via MYC and Metabolism
A multiomics study reveals how m6A RNA methylation and the reader protein HNRNPC orchestrate oncogene expression and cholesterol metabolism in T-ALL.
Summary
Researchers at Ghent University mapped the m6A RNA methylation landscape in T-cell acute lymphoblastic leukemia (T-ALL) for the first time, revealing widespread epitranscriptomic alterations. They found that HNRNPC, an m6A reader protein transcriptionally activated by the oncogene MYC, is essential for leukemia cell survival by stabilizing oncogenic transcripts and supporting cholesterol biosynthesis. Additionally, the m6A eraser enzyme FTO is significantly overexpressed in T-ALL compared to normal cells and other leukemia types. Preclinical targeting of FTO suppressed leukemia growth and synergized with standard therapies, pointing toward novel therapeutic strategies for this aggressive blood cancer.
Detailed Summary
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with limited treatment options for relapsed or refractory disease. RNA homeostasis—the regulation of transcript stability, translation, and splicing—is increasingly recognized as dysregulated in cancer, but the specific role of N6-methyladenosine (m6A) RNA methylation in T-ALL had not been systematically characterized until this study.
Using a comprehensive multiomics approach including m6A sequencing, RNA-seq, ChIP-seq, and metabolic profiling across T-ALL patient samples and cell lines, the investigators mapped the global m6A landscape in T-ALL for the first time. They identified widespread alterations in m6A deposition compared to normal T-cells, with enrichment on transcripts involved in the MYC oncogenic pathway and cholesterol biosynthesis—two critical drivers of T-ALL proliferation and survival.
A central discovery was the dependency of T-ALL on HNRNPC (heterogeneous nuclear ribonucleoprotein C), a cytoplasmic m6A reader protein. HNRNPC expression is directly transcriptionally controlled by MYC, creating a feedback loop in which the oncogene amplifies m6A-dependent post-transcriptional regulation. Silencing HNRNPC dramatically impaired oncogenic signaling, destabilized key cancer-promoting transcripts, disrupted cholesterol metabolism, and severely curtailed leukemia cell proliferation and viability both in vitro and in preclinical models.
The study also characterized the m6A demethylase FTO (fat mass and obesity-associated protein), finding its levels significantly elevated in T-ALL cells relative to normal hematopoietic cells and other leukemia subtypes. Pharmacological inhibition of FTO demonstrated therapeutic efficacy in preclinical T-ALL models and showed synergy with clinically relevant therapeutics currently used in treatment protocols, suggesting FTO inhibition could enhance existing therapeutic strategies.
Together, these findings establish m6A RNA methylation as a fundamental regulatory layer in T-ALL oncobiology, with HNRNPC and FTO as actionable therapeutic targets. The work highlights that targeting the epitranscriptome—the chemical modifications on RNA—represents a promising and underexplored avenue for T-ALL treatment, particularly for patients with relapsed or refractory disease where current options are inadequate.
Key Findings
- HNRNPC, an m6A reader, is transcriptionally driven by MYC and essential for T-ALL cell survival and oncogenic signaling.
- Global m6A RNA methylation is extensively altered in T-ALL patients, affecting MYC pathway and cholesterol biosynthesis transcripts.
- HNRNPC silencing profoundly disrupts oncogenic transcription, cholesterol metabolism, and leukemia cell growth.
- FTO demethylase is significantly overexpressed in T-ALL versus normal cells and other leukemia types.
- FTO inhibition shows preclinical anti-leukemia efficacy and synergizes with existing T-ALL therapeutics.
Methodology
The study employed a multiomics strategy combining m6A sequencing (MeRIP-seq), RNA-seq, ChIP-seq, and metabolic profiling in T-ALL patient samples and established cell lines. HNRNPC dependency was validated through genetic silencing experiments and preclinical leukemia models. FTO inhibition was tested pharmacologically in cell lines and in vivo preclinical models with combination therapy assessments.
Study Limitations
The full paper XML body was restricted by publisher, limiting access to complete methodological details, patient cohort sizes, and granular statistical data. Clinical translation remains preclinical, and the specific T-ALL molecular subtypes most responsive to FTO or HNRNPC targeting have not yet been definitively established. Long-term safety and specificity of FTO inhibition in normal hematopoietic cells require further evaluation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.